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Edited by Vladimir SkulachevAbstract The mitochondria-targeted antioxidant MitoQ com-
prises a ubiquinol moiety covalently attached through an
aliphatic carbon chain to the lipophilic triphenylphosphonium
cation. This cation drives the membrane potential-dependent
accumulation of MitoQ into mitochondria, enabling the ubiqui-
nol antioxidant to prevent mitochondrial oxidative damage far
more eﬀectively than untargeted antioxidants. We sought to
ﬁne-tune the hydrophobicity of MitoQ so as to control the
extent of its membrane binding and penetration into the
phospholipid bilayer, and thereby regulate its partitioning
between the membrane and aqueous phases within mitochondria
and cells. To do this, MitoQ variants with 3, 5, 10 and 15 carbon
aliphatic chains were synthesised. These molecules had a wide
range of hydrophobicities with octan-1-ol/phosphate buﬀered
saline partition coeﬃcients from 2.8 to 20 000. All MitoQ
variants were accumulated into mitochondria driven by the
membrane potential, but their binding to phospholipid bilayers
varied from negligible for MitoQ3 to essentially total for
MitoQ15. Despite the span of hydrophobicites, all MitoQ
variants were eﬀective antioxidants. Therefore, it is possible to
ﬁne-tune the degree of membrane association of MitoQ and
other mitochondria targeted compounds, without losing antiox-
idant eﬃcacy. This indicates how the uptake and distribution of
mitochondria-targeted compounds within mitochondria and cells
can be controlled, thereby facilitating investigations of mito-
chondrial oxidative damage.
 2004 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Mitochondrial oxidative damage contributes signiﬁcantly
to a range of degenerative diseases [1–5] and the production
of reactive oxygen species (ROS) by mitochondria may be
an important redox signal [6,7]. Consequently, there is
considerable interest in selectively blocking mitochondrial
oxidative damage and ROS production to determine the role
of mitochondria in redox signalling and to develop therapies
[3]. Towards these goals, we developed mitochondria-tar-
geted antioxidants that selectively block mitochondrial oxi-
dative damage [8–11]. These compounds comprise
antioxidants covalently linked to triphenylphosphonium, a
lipophilic cation that accumulates several-hundred fold
within mitochondria driven by the large membrane potential
(negative inside) [12]. The most eﬀective is MitoQ, an anti-
oxidant ubiquinol moiety attached to a triphenylphospho-
nium cation by an aliphatic carbon chain [13] (Fig. 1A). The
selective accumulation of MitoQ prevents mitochondrial
oxidative damage far more eﬀectively than untargeted an-
tioxidants [13–15]. Mitochondria-targeted antioxidants have
potential as therapies, because they are taken up into mi-
tochondria in vivo following oral administration [16], and
they have also been used to probe the role of mitochon-
drial ROS production in redox signalling and metabolic
regulation [17–19].
The uptake into mitochondria and binding to phospholipid
bilayers of alkyl triphenylphosphonium cations such as MitoQ
have been explored in detail [8,20,21]. To enter mitochondria,
alkyltriphenylphosphonium cations ﬁrst bind to the outer
surface of the inner membrane, then permeate the hydrophobic
potential energy barrier of the phospholipid bilayer, before
binding to the inner surface of the membrane from where they
desorb into the mitochondrial matrix [8,20] (Fig. 1A). In the
presence of a membrane potential there is 100 to 1000-fold
accumulation of the cation into the matrix, the extent of which
is determined by the Nernst equation [22] (Fig. 1A). Alkyltri-
phenylphosphonium cations are in equilibrium between those
free in solution and those adsorbed as a monolayer on the
membrane surface, with the more hydrophobic the alkyl chain
the greater the proportion of cation that is membrane bound
[22]. This is illustrated in Fig. 1B, which shows how [10-(4,5-
dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]-
triphenylphos-phonium (MitoQ10) is thought to interact with
phospholipid bilayers. The membrane-bound triphenylphos-
phonium cation is located in a potential energy well at the level
of the phospholipid carbonyls, while the alkyl chain insertsblished by Elsevier B.V. All rights reserved.
Fig. 1. Uptake of MitoQ by mitochondria. (A) The uptake of
MitoQ10 into an energised mitochondrion in response to the
membrane potential (Dw) is shown schematically. (B) The predicted
position of MitoQ10 adsorbed to the matrix surface of the inner
membrane is modelled relative to a simple phospholipid with the
triphenylphosphonium moiety adsorbed to the membrane surface at
the level of the fatty acid carbonyls, and the alkyl chain and ubi-
quinol moiety inserted into the hydrophobic core of the phospho-
lipid bilayer.
10 J. Asin-Cayuela et al. / FEBS Letters 571 (2004) 9–16into the phospholipid bilayer [22,23] (Fig. 1B). Consequently,
increasing the length and hydrophobicity of the alkyl side
chain probably increases both the extent of binding of al-
kyltriphenylphosphonium cations to phospholipid bilayers
and the depth of side chain penetration into the membrane
[22,23].
While MitoQ shows promise as both a therapy and as an
experimental tool, its ten carbon alkyl chain makes it signiﬁ-
cantly more hydrophobic than the simple lipophilic cation
methyltriphenylphosphonium (TPMP) [13]. Consequently,
much of the MitoQ taken up into mitochondria is bound to the
matrix-facing surface of the inner membrane with little free in
the matrix [8,13]. The hydrophobicity of MitoQ also aﬀects its
intracellular distribution as it increases its binding to non-mi-tochondrial membranes, decreases its oral bioavailability [16],
lowers its water solubility and renders it hygroscopic and dif-
ﬁcult to crystallise. Therefore, it may be beneﬁcial to manip-
ulate the hydrophobicity of MitoQ to see how its ability to
prevent mitochondrial oxidative damage is aﬀected. Knowl-
edge of alkyltriphenylphosphonium cations suggests that
altering the length of the alkyl chain linking the triphenyl-
phosphonium and the ubiquinol is a good way to change the
hydrophobicity of MitoQ. Such an alteration is predicted to
modulate the ability of MitoQ to prevent lipid peroxidation by
changing both its extent of membrane adsorption and also
how far the antioxidant inserts into the phospholipid bilayer
(Fig. 1B). However, it is not known if altering the length of the
alkyl chain would change MitoQ membrane binding suﬃ-
ciently, or whether it would be counterproductive by disrupt-
ing its antioxidant eﬃcacy and mitochondrial uptake.
For all these reasons, we sought to alter the hydropho-
bicity of MitoQ by changing the length of the alkyl chain so
as to ﬁne-tune its membrane binding, free concentration in
the mitochondrial matrix and its depth of penetration into
the membrane. Here, we report on the synthesis and char-
acterisation of MitoQ variants with 3, 5, 10 and 15 carbon
alkyl chains. These MitoQ variants had widely diﬀering
hydrophobicities and extents of binding to phospholipid
bilayers. However, they retained their antioxidant eﬃcacy
and ability to be taken up into mitochondria driven by the
membrane potential. These ﬁndings indicate that the prop-
erties of MitoQ, and of other mitochondria-targeted mole-
cules, can be manipulated rationally in order to ﬁne-tune
their membrane binding and distribution within mitochon-
dria and cells.2. Materials and methods
2.1. Chemical syntheses
MitoQ10 was synthesised as the bromide salt as previously described
[13]. The chemical syntheses of [3-(4,5-dimethoxy-2-methyl-3,6-dioxo-
1,4-cyclohexadien-1-yl)propyl]triphenylphosphonium (MitoQ3), [5-(4,
5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)pentyl]tri-
phenylphosphonium (MitoQ5) and [15-(4,5-dimethoxy-2-methyl-3,
6-dioxo-1,4-cyclohexadien-1-yl)pentadecyl]triphenylphosphonium (Mi-
toQ15) are outlined in Fig. 2 and are described in the on-line supple-
mentary material. Nuclear magnetic resonance spectra were acquired
using a Varian 300 MHz instrument. For 1H NMR, tetramethylsilane
was the internal standard in CDCl3. For
31P NMR, 85% phosphoric
acid was the internal standard. Chemical shifts (d) are in ppm relative
to the internal standard. Elemental analyses were done by the Camp-
bell Microanalytical Laboratory, University of Otago. Electrospray
mass spectrometry was done using a Shimadzu LCMS-QP800X liquid
chromatography mass spectrometer. Stock solutions were prepared in
absolute ethanol and stored at )20 C in the dark.
2.2. Partition coeﬃcients
To measure the octan-1-ol/phosphate buﬀered saline (PBS) parti-
tion coeﬃcients of TPMP, MitoQ3 and MitoQ5, we used our previ-
ously published method [13]. This was done by adding 400 nmol of
the compound to 2 ml PBS-saturated octan-1-ol and mixing for 30
min at 37 C with 2 ml octan-1-ol saturated PBS in a glass Kimax
tube. The concentrations of the compound in the two phases were
measured by UV absorption at 268 nm and quantitated from stan-
dard curves of the compound in octan-1-ol saturated PBS, or PBS-
saturated octan-1-ol [13,28]. For the more hydrophobic compounds,
this procedure was found to be inaccurate due to the low concen-
trations in the aqueous phase, insolubility in aqueous buﬀer causing
adsorption during analysis and the need for standard curves in PBS
and octan-1-ol. Therefore, for MitoQ10 and MitoQ15 100 ll of a 4
OO
MeO
MeO
Me
PPh3
O
O
MeO
MeO
Me
Ce(NH4)2 (NO3)6
NHOOC COOH
1. NaBH4, MeOH
2. Me2SO4, NaOH
OMe
Me
OMe
MeO
MeO
Br
OMe
OMe
MeMeO
MeO
OMe
MeO
MeO
OMe
Me
OH
MeSO2Cl
OMe
MeO
MeO
OMe
Me
(CH2)3-OSO2Me
NaI
PPh3
OMe
Me
OMe
MeO
MeO
PPh3
1. n-BuLi, TMEDA
Hexane
2. CuCN,
9-BBN
I
I
O
O
MeMeO
MeO OH
O
O
MeMeO
MeO I
OH
OH
MeMeO
MeO PPh3
O
O
MeMeO
MeO PPh3
OH
OH
MeMeO
MeO BF3.Et2O
HOAc
LiAlH4
THF
OH
MeMeO
MeO
OH
OH
OH
MeMeO
MeO
OH
I
OTHP
OH
MeMeO
MeO O
O
HOAc
OAc
MeO
MeO
OAc
Me
OAc
NaBH4
PPh3
H2/Pd/C
O2/NO2
1. CH3SO2Cl
2. NaI, acetone
O2/NO2
I
I
A B
C
O
O
MeMeO
MeO
O
O
MeMeO
MeO (CH2)15
HO(CH2)15COOH
OH
O
O
MeMeO
MeO (CH2)15
PPh3
Br
K2S2O8, AgNO3 Ph3P, 
Ph3PHBr
1
2
3
4 5
6
7
15
12
89
10 11
13
14
16
Fig. 2. Synthetic pathways. (A) MitoQ3. (B) MitoQ5. (C) MitoQ15.
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ol-saturated PBS in a glass Kimax tube at 37 C and shaken for 5
min, then centrifuged at 1000 g for 1 min to separate the phases. A
portion (25 ll) of the upper octan-1-ol phase was diluted with 975 ll
of PBS-saturated octan-1-ol and the absorbance measured at 275 nm.
The aqueous phase (10 ml) was removed to a clean Kimax tube and
the MitoQ was re-extracted into 1 ml octan-1-ol. One re-extraction
was suﬃcient to ensure that >99% of the MitoQ was removed from
the aqueous phase, and as both measurements were in octan-1-ol no
standard curves were required. The values obtained for MitoQ5 were
the same by both procedures, however, for determining the partition
coeﬃcient of MitoQ5 by the second method further octan-1-ol
extractions were required.
2.3. Preparation and incubation of mitochondria and mitochondrial
membranes
Rat liver mitochondria were prepared by homogenisation followed
by diﬀerential centrifugation in ice-cold buﬀer containing 250 mM
sucrose, 5 mM Tris–HCl, and 1 mM EGTA, pH 7.4 [29]. The protein
concentration was determined by the biuret assay using BSA as a
standard [30]. Mitochondrial membrane potential was measured by
adding 500 nM TPMP supplemented with 50 nCi [3H]TPMP (Amer-
ican Radiolabelled Chemicals Inc, MO, USA) to mitochondria sus-
pended in KCl medium (120 mM KCl, 10 mM HEPES, pH 7.2, and 1
mM EGTA) at 25 C [31]. After incubation, the mitochondria were
pelletted by centrifugation and the amounts of [3H]TPMP in the su-
pernatant and pellets were quantitated by scintillation counting and
the membrane potential calculated assuming a mitochondrial volume
of 0.5 ll/mg mitochondrial protein and a TPMP binding correction of
0.4 [32].2.4. Measurement of MitoQ uptake using an ion-selective electrode
To measure the uptake of MitoQ cations by energised mitochondria,
an ion-selective electrode was constructed [8,33,34]. The electrode and
a Ag/AgCl reference electrode were inserted through the air-tight
Perspex lid of a stirred and thermostatted 3 ml incubation chamber at
30 C, provided with an injection port for the addition of substrates.
To measure MitoQ uptake, rat liver mitochondria (1 mg protein/ml)
were incubated at 30 C in KCl medium (120 mM KCl, 10 mM HE-
PES, pH 7.2, and 1 mM EGTA) and nigericin (1 lg/ml), rotenone (8
lg/ml), succinate (10 mM) and carbonylcyanide-p-triﬂuorometho-
xyphenylhydrazone (FCCP) (500 nM) were added where indicated.
The output from the ion-selective electrode was passed to a PowerLab
Data acquisition system via a front-end pH ampliﬁer and analysed
using Chart software, all from ADInstruments.
2.5. Lipid peroxidation assays
To quantitate lipid peroxidation, the thiobarbituric acid reactive
species (TBARS) assay was used. Rat liver mitochondria (2 mg pro-
tein/ml) were incubated in 0.8 ml medium containing 100 mM KCl, 10
mM Tris–HCl and pH 7.6, at 37 C, supplemented with either 10 mM
succinate and 8 lg/ml rotenone, or an ATP regenerating system of 2.5
mM ATP, 1 mM phosphoenolpyruvate and 4 U/ml pyruvate kinase.
The appropriate MitoQ (5 lM) was then added and after 30 s the
mitochondria were exposed to oxidative stress by addition of 50 lM
FeCl2/300 lMH2O2 for 15 min at 37 C. After the incubation, 64 ll of
2% (w/v) butylated hydroxytoluene in ethanol was added, followed by
200 ll of 35% (v/v) HClO4 and 200 ll of 1% (w/v) thiobarbituric acid.
Samples were then incubated for 15 min at 100 C, centrifuged (5 min
at 12 000 g) and the supernatant transferred to a glass tube. After
addition of 3 ml water and 3 ml butan-1-ol, samples were vortexed,
12 J. Asin-Cayuela et al. / FEBS Letters 571 (2004) 9–16and the two phases allowed to separate. Aliquots (200 ll) of the or-
ganic layer were then analysed in a ﬂuorometric plate reader
(kEx ¼ 515 nm; kEm ¼ 553 nm) for TBARS and compared with a
malondialdehyde (MDA) standard curve prepared from 0.01 to 5 lM
1,1,3,3-tetraethoxypropane [13].3. Results and discussion
3.1. Synthesis and characterisation of MitoQ variants
A series of MitoQ variants with alkyl chains of 3, 5, 10 and
15 carbons linking the TPP cation and the ubiquinol were
synthesised as described in Section 2. MitoQ10 was synthesised
as previously described [13]. An overall synthetic route to
MitoQ3 (6) is shown in Fig. 2A and is based on reducing
2,3-dimethoxy-5-methyl-1,4-benzoquinone (CoQ0) to the hy-
droquinone [24] then methylating to give 2,3,4,5-tetrameth-
oxytoluene (1) [25]. In our hands, the three carbon side chain
was best introduced by metallation of 1 and reaction with allyl
bromide to give 2 rather than the reported process [26] in-
volving bromination and Grignard formation. Hydroboration
of 2 gave the alcohol 3 which was activated as a mesylate 4 and
displaced with triphenylphosphine to give the aromatic phos-
phonium iodide 5. In this case, it was found that the phos-
phonium salt formation was best carried out in the absence of
solvent using sodium iodide to enhance the reaction. Conver-
sion of the tetramethoxyaromatic ring in 5 into the required
dimethoxyquinone 6 was achieved using ceric ammonium ni-
trate on the nitrate salt of 5 (Fig. 2A). The methanesulfonate
salt of MitoQ3 was then obtained by anion exchange.
The synthesis of MitoQ5 (14) is outlined in Fig. 2B. This
synthesis was an improvement from initial work based on the
addition of 5-bromohexyl radicals to CoQ0 [27]. Here, the 5-
carbon chain was introduced by substitution of CoQ0 with an
electrophile derived from dihydropyran [35] followed by hy-
drogenolysis and deacetylation. Selective functionalisation of
the primary alcohol in 9 was achieved by oxidation [36,37] of
the hydroquinone to give 10 [27], followed by net overall
substitution with iodine to produce 11. Reduction of 11 fol-
lowed by phosphonium salt formation gave an oxidatively
sensitive hydroquinol phosphonium salt 13, which was con-
verted to MitoQ5 (14) by oxidation. The synthesis of MitoQ15
(16) involved the radical addition of a hydroxyalkyl radical to
CoQ0 followed by phosphonium salt formation (Fig. 2C). The
necessary hydroxyalkyl radical was obtained by oxidative de-
carboxylation of 16-hydroxyhexadecanoic acid with K2S2O8 in
the presence of AgNO3 [38].
All the MitoQ compounds are shown in Fig. 3. A subscript
indicates the number of carbons in the alkyl chains. In previ-
ous work, the MitoQ variant used had a ten carbon alkyl chain
and is here described as MitoQ10, while MitoQ is used gener-
ically to describe all chain length variants.
To determine the hydrophobicities of the MitoQ com-
pounds, we measured their octan-1-ol/PBS partition coeﬃ-
cients. For the more hydrophobic compounds, we were
concerned that the usual method was inaccurate; therefore, we
devised a new procedure in which we re-extracted and con-
centrated the small amount of hydrophobic compound in the
aqueous phase back into octan-1-ol before measurement, to
facilitate its quantitation. As both samples were measured in
octan-1-ol, a standard curve was not required. This procedure
gave the same partition coeﬃcient for MitoQ5 as the publishedmethod. However, the new method gave a signiﬁcantly higher
partition coeﬃcient for MitoQ10 than the one reported previ-
ously, due to systematic errors in the earlier method [13];
therefore, the new procedure was used for MitoQ10 and Mi-
toQ15. From their octan-1-ol/PBS partition coeﬃcients
(Fig. 3), it is clear that MitoQ3, MitoQ5, MitoQ10 and MitoQ15
span a wide range of hydrophobicities. That of MitoQ3 is
similar to the simple, relatively water soluble TPMP cation,
while that of MitoQ15 indicates that it has very low water
solubility. Alkyltriphenylphosphonium cations such as MitoQ
are thought to adsorb onto phospholipid bilayers with the
cation at the level of the carboxylic acid groups, while the
hydrophobic alkyl group penetrates into the hydrophobic core
of the membrane (Fig. 1B). Consequently, the longer the alkyl
chain the deeper the antioxidant ubiquinol is likely to pene-
trate into the hydrophobic core of the membrane. The maxi-
mum extent to which penetration into one leaﬂet of the
membrane will occur for these compounds is illustrated in
Fig. 3, which shows a molecular dimension comparison of the
MitoQ variants with a typical phospholipid. From this it is
clear that the ubiquinol moiety of MitoQ3 only penetrates
close to the membrane surface, while those of MitoQ10 and
MitoQ15 will penetrate close to the core of the phospholipid
bilayer. Therefore, we have synthesised a series of MitoQ
variants with a range of hydrophobicities and depths of pen-
etration into the phospholipid bilayer. Below we test their in-
teractions with mitochondria and their antioxidant properties.
3.2. Binding and uptake of MitoQ variants by mitochondria
To see if the MitoQ variants were taken up by mitochondria
in response to the membrane potential, an ion-selective elec-
trode was used to measure their steady-state concentrations
[8,33,34]. The response of this electrode to simple triphenyl-
phosphonium cations such as TPMP is Nernstian, with a linear
response of electrode voltage to log10[cation concentration]
and a slope of 60 mV at 30 C [33,34]. The most hydrophilic
compound, MitoQ3, also gave a Nernstian electrode response
with a slope close to 60 mV at concentrations above 10 lM.
This is illustrated by the logarithmic electrode response to se-
quential additions of 1 lM MitoQ3 in the absence of mito-
chondria (Fig. 4B). The electrode output was stable and also
responded rapidly to sequential additions of MitoQ5, MitoQ10
and MitoQ15 in the absence of mitochondria (Fig. 4D, F and
H, respectively). However, in these cases the electrode re-
sponses were not Nernstian, presumably due to the greater
hydrophobicity of the compounds. Even so, for all four com-
pounds the ion-selective electrode enabled us to measure the
free concentrations of the compounds and thus assess their
uptake by mitochondria in real time.
To measure MitoQ uptake, we ﬁrst added mitochondria to
the electrode chamber in the presence of rotenone to prevent
formation of a membrane potential (Fig. 4A, C, E and G). We
then made ﬁve sequential 1 lM additions of MitoQ to cali-
brate the electrode response, followed by the respiratory sub-
strate succinate to generate a membrane potential.
Mitochondrial energisation led to the rapid uptake of all the
MitoQ variants by the mitochondria, and subsequent addition
of the uncoupler FCCP abolished the membrane potential and
led to their rapid release from the mitochondria (Fig. 4A, C, E
and G). These experiments clearly show mitochondrial mem-
brane potential-dependent uptake of MitoQ3, MitoQ5, and
MitoQ10 (Fig. 4A, C and E). While MitoQ15 was also taken up
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J. Asin-Cayuela et al. / FEBS Letters 571 (2004) 9–16 13by mitochondria on induction of a membrane potential, the
electrode response to MitoQ15 in the presence of mitochondria
was less reliable and prone to drift (Fig. 4G). This contrasts
with the electrode response to MitoQ15 in the absence of mi-
tochondria (Fig. 4H) and is presumably due to low concen-
trations of free MitoQ15 in the presence of mitochondria.
Therefore, we next estimated the extent of MitoQ binding to
deenergised mitochondria (Fig. 4B, D, F and H). For these
experiments, the MitoQ variants were ﬁrst added to the elec-trode chamber and then mitochondria were introduced in the
presence of rotenone to prevent formation of a membrane
potential. The decrease in MitoQ concentration on adding
mitochondria is due to binding of MitoQ to the deenergised
mitochondria. (Note that this binding of hydrophobic MitoQ
variants to mitochondria means that it is not possible to
compare electrode calibrations done in the presence and ab-
sence of mitochondria.) The subsequent addition of succinate
to generate a membrane potential indicates the membrane
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were present and the MitoQ variants were then added as ﬁve sequential
1 lM additions (black arrowheads) to calibrate the electrode response.
For the right hand panels (B, D, F and H), the electrodes were ﬁrst
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tion of the more hydrophobic compounds MitoQ10 and MitoQ15,
much of the added compound will be bound to the mitochondria and
will therefore not be free in solution. As the electrode responds to the
free concentration, the electrode responses to additions of MitoQ10
and MitoQ15 in the presence or absence of mitochondria are not
comparable and the scales have been adjusted to make each experi-
mental trace roughly the same size. In all cases, succinate was added to
generate a membrane potential and FCCP was added to dissipate it.
Data are typical traces of experiments repeated at least 2–3 times.
MIT, mitochondria; SUC, succinate.
14 J. Asin-Cayuela et al. / FEBS Letters 571 (2004) 9–16potential dependent uptake of the compounds, which is then
reversed by addition of FCCP to abolish the membrane po-
tential. The free concentration of MitoQ3 was unaﬀected by
addition of mitochondria, indicating that negligible amounts
of MitoQ3 bind to deenergised mitochondria (Fig. 4B). The
FCCP-sensitive uptake of MitoQ3 on energisation with succi-
nate was 3.7 nmol MitoQ3/mg protein, corresponding to an
accumulation ratio of 2 103. This is consistent with that
expected from the Nernst equation and a mitochondrial
membrane potential of about 180 mV, allowing for corrections
for intramitochondrial binding. For MitoQ5, there was some
binding of the compound to the deenergised mitochondria
(0.6 nmol/mg protein) (Fig. 4D). However, this was negligi-
ble compared to its subsequent uptake on energisation with
succinate, of 2.8 nmol MitoQ5/mg protein, corresponding to
an accumulation ratio of about 1.4 103. For MitoQ10, therewas signiﬁcant binding to deenergised mitochondria of 2.6
nmol MitoQ10/mg protein, and this was followed by further
uptake of 1 nmol/mg protein on addition of succinate
(Fig. 4F). Nearly all of the free MitoQ15 was bound to the
deenergised mitochondria, making further uptake on energi-
sation diﬃcult to detect (Fig. 4H). In contrast, the membrane
potential-dependent uptake of MitoQ15 was clearer when the
electrode was calibrated in the presence of mitochondria
(Fig. 4G) and consequently the electrode response was highly
sensitive to the small amount of free MitoQ15.
It is clear from Fig. 4 that the lengths of the alkyl chains of
the MitoQ variant determine their extents of adsorption to
mitochondrial membranes. The adsorption ranges from neg-
ligible for MitoQ3 to almost complete binding for MitoQ15. On
addition of MitoQ15 to deenergised mitochondria essentially
all the compound binds, distributed across both surfaces of the
inner and outer membranes. When a membrane potential is
induced, there will be signiﬁcant redistribution of the com-
pound to the matrix-facing surface of the inner membrane
from the outer surface of the inner membrane and from the
outer membrane. In summary, all the MitoQ variants are ta-
ken up into mitochondria driven by the membrane potential
and the longer the alkyl chain the greater their adsorption to
phospholipid bilayers.
3.3. Antioxidant eﬃcacy of MitoQ variants
We next determined how the diﬀerent lengths of alkyl
chains aﬀected the antioxidant eﬃcacy of the MitoQ vari-
ants. To do this we measured their abilities to prevent lipid
peroxidation in mitochondria, measured from the accumu-
lation of TBARS in mitochondria exposed to ferrous iron
and hydrogen peroxide (Fig. 5). For mitochondria energised
with succinate the background level of TBARS was negli-
gible, but it increased to about 3.75 nmol MDA/mg protein
on exposure to oxidative stress (Fig. 5A; black bars). High
concentrations (5 lM) of any of the MitoQ variants largely
prevented the accumulation of TBARS, while the simple
cation TPMP did not. This conﬁrms that it was the ubi-
quinol side chain of MitoQ that was responsible for the
antioxidant action and not any non-speciﬁc interactions of
the cation with mitochondria. In these experiments, succi-
nate will both maintain a membrane potential to drive the
uptake of the cations into mitochondria and also recycle the
ubiquinone form of MitoQ to the active antioxidant ubi-
quinol form [13]. To see if reduction by the respiratory
chain was required for the antioxidant eﬃcacy of MitoQ, we
incubated mitochondria in the presence of ATP and an ATP
regenerating system. ATP hydrolysis and reversal of the
mitochondrial ATP synthase led to extensive proton pump-
ing, which built up a membrane potential similar to that
generated by succinate (Fig. 5B). This leads to the same
MitoQ uptake as for mitochondria energised by succinate,
but now the MitoQ will no longer be recycled to their active
ubiquinol forms by the respiratory chain. The MitoQ com-
pounds were ineﬀective at preventing lipid peroxidation in
mitochondria energised by ATP hydrolysis (Fig. 5A, white
bars), compared with the dramatic protection seen in mito-
chondria energised by succinate (Fig. 5A, black bars).
Therefore, reduction of MitoQ variants by the respiratory
chain, as well as accumulation by the mitochondrial mem-
brane potential are required for the antioxidant eﬃcacy of
the MitoQ variants. Interestingly, lower levels of lipid per-
M
D
A
 (n
mo
l/m
g p
rot
ein
)
control
A
M
em
br
an
e 
po
te
nt
ia
l (
mV
)
B
succinate ATP
0
2
4
6
20
60
100
140
180
 MitoQ
5
MitoQ
3
 MitoQ
10
MitoQ
15
no additions
FeCl  + H  O22 2
1
2
3
4
5
6
IC
   
 (µ
M
)
MitoQ MitoQ MitoQ MitoQ3 5 10 15
MitoQ
MitoQ
MitoQ
MitoQ
3
5
10
15
0
20
40
60
80
100
0.125 0.5 1 2 5 10
C
D
Concentration (µM) 
A
nt
io
xi
da
nt
 e
ffi
ca
cy
 (%
 of
 co
ntr
ol)
50
TPMP
*
**
**
Fig. 5. Antioxidant eﬃcacy of MitoQ variants. (A) Mitochondria
were energised with succinate (black bars) or by incubation with an
ATP regenerating system consisting of ATP, phosphoenol pyruvate
and pyruvate kinase (white bars). After a 30 s preincubation with
the various MitoQ variants (5 lM), TPMP (5 lM) or carrier, oxi-
dative stress was induced by addition of 50 lM FeCl2 and 300 lM
H2O2. After 15 min incubation at 37 C, lipid peroxidation was
estimated by measuring TBARS. Data are means range of two
independent experiments. (B) The mitochondrial membrane potential
induced with succinate or with the ATP regenerating system was
measured from the accumulation of [3H]TPMP. Data are mean-
s range of duplicate determinations of a 25 min incubation. The
membrane potentials after a 5 min incubation were the same (data
not shown). (C) The concentration dependence of the prevention of
the accumulation of TBARS by MitoQ variants was measured. All
incubations were carried out in the presence of succinate as de-
scribed for (A). Results are expressed as % inhibition of TBARS
formation, taking the value of a sample exposed to FeCl2/H2O2 in
the absence of MitoQ variants as 0% inhibition, and a control
sample (no FeCl2/H2O2 added) as 100%. The data shown are a
typical titration with each concentration determined in tripli-
cateS.D. (D) The IC50 concentrations for prevention of lipid
peroxidation. Data are means S.E.M., estimated from three inde-
pendent titrations as shown in (C). The statistical signiﬁcance rela-
tive to the IC50 for MitoQ3 was determined using Student’s two
tailed t-test: *P < 0:05; **P < 0:005.
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chondria energised with succinate, compared to those en-
ergised with ATP (Fig. 5A). This is due to the protective
antioxidant eﬀect of the endogenous mitochondrial Coen-
zyme Q pool, which is held reduced in the presence of
succinate but not in the presence of ATP [39,40]. In sum-
mary, all the MitoQ variants require activation by the re-
spiratory chain to be eﬀective antioxidants.
The data described in Fig. 5A were obtained using a uni-
form concentration of 5 lM for all the MitoQ variants. To
compare their relative antioxidant eﬃcacies, we titrated the
compounds in the presence of succinate: a typical titration is
shown in Fig. 5C. This experiment suggests that the antiox-
idant eﬃcacy of these compounds correlates with the length
of the alkyl chain. To quantitate this, we calculated the IC50
values for the prevention of lipid peroxidation by the four
MitoQ variants (Fig. 5D). These measurements conﬁrmed
that the order of antioxidant eﬃcacy was: MitoQ15>Mi-
toQ10>MitoQ5>MitoQ3. As ubiquinol reactivity with ROS
will be unaﬀected by altering the length of the alkyl chain,
this indicates that antioxidant eﬃcacy correlated with both
degree of adsorption to the membrane and depth of pene-
tration into the phospholipid bilayer.3.4. Conclusions
We have synthesised a series of variants of MitoQ with alkyl
chains of 3, 5, 10 and 15 carbons. These molecules had a range
of hydrophobicities leading to wide diﬀerences in their octan-1-
ol/PBS partition coeﬃcients from 2.8 to 20 000. All the MitoQ
variants were accumulated into mitochondria driven by the
mitochondrial membrane potential, although for the most
hydrophobic compound, MitoQ15, this eﬀect was largely
masked by the extensive binding of the compound to
phospholipid bilayers. All of the compounds were eﬀective
antioxidants and for persistent antioxidant activity over 15
min all required the action of the respiratory chain to convert
MitoQ to its active antioxidant form and to recycle MitoQ
after having detoxiﬁed lipid peroxidation intermediates. The
range of membrane binding indicates that the compounds will
have diﬀerent locations within mitochondria with most of the
more hydrophobic compounds being membrane adsorbed,
while more of the hydrophilic compounds will be free in the
matrix. In addition, the non-speciﬁc binding of the less hy-
drophobic compounds will decrease non-mitochondrial bind-
ing throughout the cell. Thus, by using appropriate variants of
MitoQ it should be possible to infer the relative importance of
the ROS produced within the membrane or in the matrix.
Finally, the increased hydrophilicity of many of these MitoQ
variants will simplify their handling and may also lead
to beneﬁcial pharmacokinetic properties such as increased
bioavailability.
These ﬁndings show that it is possible to alter the aliphatic
chain linking an antioxidant moiety and a targeting lipophilic
cation but still retain mitochondrial targeting and antioxidant
potency. Furthermore, it is possible to ﬁne-tune the hydro-
phobicity of MitoQ and related compounds in order to
control their intracellular and mitochondrial location and
penetration into the membrane. This will facilitate the design
of further mitochondria-targeted compounds in order to
optimise their use as probes of the role of mitochondrial
oxidative damage in cell signalling and pathology.
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